Eleva Capital’s Mineralys Therapeutics MLYS Stock Holding History

Eleva Capital’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-17,081	Closed	-$463K	–	36
2026 Q2	$463K	Hold	17,081	–	–	0.13%	17
2026 Q1	$463K	Buy	+17,081	New	+$501K	0.13%	17

Other funds holding MLYS

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Eleva Capital's MLYS Position: Q3 2026 in Review

Eleva Capital sold out of Mineralys Therapeutics (MLYS) in Q3 2026, closing a stake of 17,081 shares — an estimated $463K sold.

Eleva Capital first reported a position in MLYS in Q1 2026 and held it in 2 quarters. The position peaked at $463K in Q2 2026. 2 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

Eleva Capital reported no remaining Mineralys Therapeutics position as of Q3 2026 after selling out during the quarter.
Eleva Capital sold 17,081 Mineralys Therapeutics shares in Q3 2026, an estimated $463K.
Eleva Capital first reported a position in Mineralys Therapeutics in Q1 2026 and held it in 2 quarters.
Eleva Capital's Mineralys Therapeutics position peaked at $463K in Q2 2026.
2 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Eleva Capital's 13F filing for Q3 2026, filed 6 Oct 2026.